Clinical Trial: Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years

U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07905989) titled 'Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years' on June 22.

Brief Summary: Recently the era of direct-acting antiviral drugs for hepatitis C treatment has changed the world map of HCV. Results in adults are promising. FDA approved only two drugs in the pediatric age group 12 to 17 years. Younger children are still on the wait list for treatment. The current study aimed to study the efficacy and safety of combined sofosbuvir (SOF)/daclatasvir (DCV) in children with hepatitis C virus infection aged 6-18 years.

Study Start Date: Dec. 18, 2023

Study Type: INTERVENTIONAL

Condition: Hepatitis C,Chronic Ch...